Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 29, 2010

Helmholtz Zentrum München and Sirion Biotech Partner to Study Lentiviruses in Lymphoma

  • Helmholtz Zentrum München and Sirion Biotech are allying to develop new therapeutic approaches against lymphoid tumors. With a two-year €500,000 grant (about $672,369) from the Federal Ministry for Economics and Technology, the partners will seek to further lentiviral vector systems to better understand the disease mechanisms of this cancer form and to create new treatments.

    Helmholtz Zentrum München and Sirion Biotech seek to optimize the use of lentiviruses as gene vectors for hematopoietic cells. “We want to specifically refine the lentiviral vectors to target the tumor cell markers,” explains Nataša Anastasov, who is in charge of the project at the Institute of Radiation Biology of Helmholtz Zentrum München.

    To achieve this the researchers will first develop new cell lines with improved binding characteristics for virus production. Sirion Biotech, founded in 2006, focuses on producing genetically modified cells and providing technology related to viral vector systems.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »